NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
申请人:Nissan Chemical Industries, Ltd.
公开号:EP2025671A1
公开(公告)日:2009-02-18
Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.
A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
提供了对预防、治疗或改善血栓生成素受体活化有效的疾病的化合物。
由式(I)代表的化合物(其中 R1、R2、R3、L1、L2、L3、X 和 Y 在描述中定义)、该化合物的同系物、原药或药学上可接受的盐或其溶液。
Therapeutic compounds and uses thereof
申请人:Distefano Peter
公开号:US20050187237A1
公开(公告)日:2005-08-25
Compounds of formula (I) are described herein
The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.
Compounds of formulas (I), (II), (III), and (IV)
and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.